Everence Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Everence Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$377K	Buy	6,584 +973	+17%	+$53.3K	0.02%	541
2026 Q1	$317K	Buy	+5,611	New	+$327K	0.02%	548
2025 Q4	–	Sell	-7,616	Closed	-$412K	–	786
2025 Q3	$412K	Sell	7,616 -1,824	-19%	-$104K	0.02%	462
2025 Q2	$519K	Buy	9,440 +4,370	+86%	+$257K	0.03%	367
2025 Q1	$358K	Hold	5,070	–	–	0.02%	488
2024 Q4	$333K	Buy	+5,070	New	+$340K	0.02%	530

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Everence Capital Management's BMRN Position: Q2 2026 in Review

Everence Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 17% in Q2 2026, buying an estimated $53.3K and bringing the position to 6,584 shares worth $377K. The position accounts for 0.02% of the portfolio, ranked #541.

Everence Capital Management first reported a position in BMRN in Q4 2024 and has held it in 6 quarters since. The position peaked at $519K in Q2 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Everence Capital Management held 6,584 shares of BioMarin Pharmaceuticals worth $377K as of Q2 2026.
Everence Capital Management bought 973 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $53.3K.
BioMarin Pharmaceuticals made up 0.02% of Everence Capital Management's portfolio in Q2 2026, its #541 holding.
Everence Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Everence Capital Management's BioMarin Pharmaceuticals position peaked at $519K in Q2 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.